Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 5—May 2024
Research

Mpox Diagnosis, Behavioral Risk Modification, and Vaccination Uptake among Gay, Bisexual, and Other Men Who Have Sex with Men, United Kingdom, 2022

Dana OgazComments to Author , Qudsia Enayat, Jack R.G. Brown, Dawn Phillips, Ruth Wilkie, Danielle Jayes, David Reid, Gwenda Hughes, Catherine H. Mercer, John Saunders, Hamish Mohammed, and UK Health Security Agency Sexual Health Liaison Group1
Author affiliations: UK Health Security Agency, London, UK (D. Ogaz, Q. Enayat, D. Phillips, R. Wilkie, D. Jayes, G. Hughes, J. Saunders, H. Mohammed); The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK (D. Ogaz, J.R.G. Brown, D. Reid, G. Hughes, C.H. Mercer, J. Saunders, H. Mohammed); University College London, London, UK (D. Reid, C.H. Mercer, J. Saunders); London School of Hygiene & Tropical Medicine, London, UK (G. Hughes)

Main Article

Table 3

Mpox vaccine offer and uptake among participants in a survey of mpox diagnosis, behavioral risk modification, and vaccination uptake among gay, bisexual, and other men who have sex with men, United Kingdom, 2022*

Eligibility group Mpox vaccine offered and vaccinated, no. (%)
 Mpox vaccination uptake, % (95% CI)
Total offered vaccine Offered, vaccinated Offered, not vaccinated Not offered, not vaccinated Among those offered vaccine† All participants‡
Eligible, n = 875 655 (75) 601 (69) 54 (6)§ 220 (25)¶ 92 (89–94) 69 (65–72)
Not eligible, n = 458 116 (25) 91 (20) 25 (5) 342 (75) 78 (70–86) 20 (16–24)
All participants, n = 1,333 771 (58) 692 (52) 79 (6)# 562 (42)** 90 (88–92) 52 (49–55)

*Participants were eligible for mpox vaccination if they self-reported any of the following: meeting recent male physical sex partners at sex on premises venues, sex parties, or public sex environment (i.e., cruising grounds) since August 2022; >10 recent male physical sex partners since August 2022; recreational drug use associated with chemsex in the past year; recent positive STI test since August 2022; or current HIV PrEP use since December 2021. Percentages may not total 100 due to rounding. PrEP, pre-exposure prophylaxis; SHS, sexual health service, STI, sexually transmitted infection. †Percentage (%) reporting uptake of >1 mpox vaccine dose among those offered an mpox vaccine [(a/(a+b)) × 100%]. ‡Percentage (%) reporting uptake of >1 mpox vaccine dose among all groups [(a/(a+b+c)) × 100%]. §Among participants who were eligible for mpox vaccine eligible and offered a vaccine, but not vaccinated (n = 54), 28 (52%) were waiting to get vaccinated, 26 (48%) decided not to get vaccinated. ¶Among those eligible and not offered, 38% (83/220) had visited an SHS since August 2022 and 57% (126/220) had visited an SHS in the past year. #Among all participants offered an mpox vaccine, but not vaccinated (n = 79), 42 (53%) were waiting to get vaccinated, 37 (47%) decided not to get vaccinated. **Among participants not offered an mpox vaccine, 20% (111/562) had visited an SHS since August 2022 and 32% (182/562) had visited an SHS in the past year.

Main Article

1Members of this group are listed at the end of this article.

Page created: March 06, 2024
Page updated: April 23, 2024
Page reviewed: April 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external